Table 3 Clincial Trials testing Live-attenuated MeV-derived vaccines.

From: Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

Trial number

Virus

Disease

Phase

Institution

Status

Refs.

EudraCT 2013-001084-23

MV-CHIK

Chikungunya fever

I

Themis Biosciences

Completed

93

NCT01320176

MV1-F4-CT1

AIDS

I

Institut Pasteur

Completed

 

NCT02861586

MV-CHIK

Chikungunya fever

II

Themis Biosciences

Completed

91,98

NCT02996890

MV-ZIKA

Zika fever

I

Themis Biosciences

Completed

 

NCT03028441

MV-CHIK

Chikungunya fever

I

NIAID

Completed

 

NCT03101111

MV-CHIK

Chikungunya fever

II

Themis Biosciences, Walter Reed Army Institute of Research

Completed, results posted

 

NCT03635086

MV-CHIK

Chikungunya fever

II

Themis Biosciences

Completed, results posted

 

NCT03807843

MV-CHIK

Chikungunya fever

II

Themis Biosciences, Walter Reed Army Institute of Research

Completed, results posted

 

NCT04033068

MV-ZIKA-RSP

Zika fever

I

Themis Biosciences

Completed, results posted

 

NCT04055454

MV-LASV

Lassa fever

I

Themis Biosciences

Completed

 

NCT04497298

TMV-083 / V-591

COVID-19

I

Institut Pasteur, Themis Biosciemces, CEPI

Completed

35

NCT04498247

V591

COVID-19

I / II

Merck Sharp & Dohme

Terminated

36

  1. Listed are clinical trials testing recombinant MeV-derived vaccines as identified in public databases with increasing clinical trial designation number.